An audit on diabetes management in Asian patients treated by specialists: the Diabcare-Asia 1998 and 2003 studies

References

• UK Prospective Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999;22: 1125–36
   Google Scholar
• Weinger K, Jacobson AM. Psychosocial and quality of life correlates of glycemic control during intensive treatment of type 1 diabetes. Patient Educ Couns 2001;42:123–31
   PubMed Web of Science ®Google Scholar
• Rubin R, Peyrot M. Psychosocial problems and interventions in diabetes: a review of the literature. Diabetes Care 1995;15:1640–57
   Google Scholar
• Musselman DL, Betan E, Larsen H, Phillips LS. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry 2003;54:317–29
   PubMed Web of Science ®Google Scholar
• Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001;24:1069–78
   PubMed Web of Science ®Google Scholar
• Peyrot M, Rubin RR, Lauritzen T, et al. Psychosocial problems and barriers to improved diabetes management: results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study. Diabet Med 2005;22:1379–85
   PubMed Web of Science ®Google Scholar
• Nitiyanant W, Tandhanand S, Mahtab H, et al. The Diabcare-Asia 1998 Study – outcomes on control and complications in type 1 and type 2 diabetic patients. Curr Med Res Opin 2002;18:317–27
   PubMed Web of Science ®Google Scholar
• Chuang LM, Tsai ST, Huang BY, Tai TY on behalf of the Diabcare-Asia 1998 Study Group. The status of diabetes control in Asia – a cross-sectional survey of 24,317 patients with diabetes mellitus in 1998. Diabet Med 2002;19: 978–85
   Google Scholar
• World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000
   Google Scholar
• Asia-Pacific Type 2 Diabetes Policy Group. Type 2 Diabetes – Practical Targets and Treatments, 3rd edn. Health Communications Australia: Sydney, Australia, 2002
   Google Scholar
• Bech P, Moses R, Gomis R. The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy-naïve Type 2 diabetes: a placebo-controlled, multicentre study. Qual Life Res 2003;12: 413–25
   Google Scholar
• Shea S, Skovlund S, Bech P, et al. Routine assessment of psychological well-being in people with diabetes – validation of the WHO-5 Well-Being Index in six countries. Diabetologia 2003;46 (Suppl 2):A88
   Google Scholar
• Anonymous. The Oxford International Diabetes Summit: Implications of the DAWN study. Pract Diab Int 2002;19:187–92
   Google Scholar
• Soren ES, Peyrot M on behalf of the DAWN International Advisory Panel. The Diabetes, Attitudes, Wishes, and Needs (DAWN) Program: A new approach to improving outcomes of diabetes care. Diabetes Spectrum 2005; 18: 136–42
   Google Scholar
• Alberti G. The DAWN (Diabetes Attitudes, Wishes and Needs) Study. Pract Diab Int 2002;19:22–24a
   Google Scholar
• Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes 2002;26 (Suppl 3):S18–24
   PubMed Web of Science ®Google Scholar
• Peyrot M, Rubin RR, Lauritzen T, et al. on behalf of the International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673–9
   Google Scholar
• Turner R, Murchison L, Wright AD, et al. United Kingdom prospective diabetes study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998;128:165–75
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005–12
   PubMed Web of Science ®Google Scholar
• Pibernik-Okanovic M, Szabo S, Metelko Z. Quality of life following a change in therapy for diabetes mellitus. Pharmacoeconomics 1998;14:201–7
   Google Scholar
• Anonymous. 2nd International DAWN Summit: a call-to-action to improve psychosocial care for people with diabetes. Pract Diab Int 2004;21:201–8
   Google Scholar